New embryo transfer device aims to boost IVF success
NCT ID NCT06744049
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new device called the Transfer Direct System (TDS) for embryo transfer during IVF. The device uses a camera and automated system to place the embryo directly into the uterine lining, which may reduce the chance of the embryo being expelled. Researchers will compare TDS to standard transfer in 80 women to see if it is safer and leads to more pregnancies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Transfer Direct System (TDS) - a semi-automated medical device for embryo transfer
- What this could lead to
- If successful, this device could make embryo transfer more precise and reliable, potentially improving IVF success rates and reducing the number of failed cycles.
- What could go wrong
- This is an early-stage trial with only 80 participants, so results may not apply to everyone. The device is new, and its safety and effectiveness compared to standard transfer are still being tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 50 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients whose written informed consent is obtained, approved by the Ethics Committees for Investigation with Medicinal Products (ECRmp) after being duly informed of the nature of their disease and after voluntarily accepting the treatment program, knowing the potential risks, benefits, and inconveniences. 2. Patients who are going to undergo ART with a SET and have at least one vitrified euploid blastocyst with PGT-A (Preimplantation Genetic Test for the detection of Aneuploidy). 3. Women of reproductive age between 18 and 50 years (both inclusive) 4. Body mass index (BMI): \<30 kg/m2 5. Absence of adenomyosis and endometriosis 6. Uterus without pathologies that can contraindicate the transfer or may hinder implantation (e.g., polyps, fibroids that come into contact with the cavity, or Asherman syndrome) or without a history of thin endometrium or irregular patterns in thin endometrial preparations. 7. Absence of immune pathologies (e.g., lupus) that could endanger the health of the patient. 8. Easy transfer test or history of embryo transfer without difficulty or factors that indicate that the transfer is easy. Exclusion Criteria: 1. Difficult or very painful transfer tests. 2. Pathologies of an oncological nature. 3. The existence of serious or uncontrolled bacterial, fungal, or viral infections that, in the opinion of the principal investigator, may interfere with the patient's participation in the study or the evaluation of its results. 4. Other circumstances or difficulties that, in the opinion of the investigator, may pose a risk to the subject or reduce the chances of obtaining satisfactory data to achieve the objectives of the study, such as a history of severe preeclampsia without assessment by the obstetric team, psychiatric pathologies without prior assessment by the psychiatrist, uncontrolled or destabilized cardiac pathologies.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Embryo transfer are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Clínica FIV Valencia
RECRUITINGValencia, Valencia, 46021, Spain
-
Clínica Next Fertility Valencia
RECRUITINGValencia, Spain
-
Clínica Vida Recoletas Sevilla
RECRUITINGSeville, 41092, Spain
-
Dexeus Mujer Barcelona
NOT_YET_RECRUITINGBarcelona, Barcelona, 08028, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple twist during embryo transfer could boost IVF success
- Could a fibroid drug help women with adenomyosis finally achieve a live birth?
- New drug may boost IVF success by thickening uterine lining
- Cervical mucus may hold key to better IVF timing
- AI embryo selector tested in IVF study
- Smaller follicles, bigger flexibility? new study tests ovulation timing in IVF